Getting sick once in a while is normal. But being sick on repeat, again and again, without answers, isn’t. For many people living with persistent infections, the experience can be exhausting, frustrating, and lonely. And far too often, it takes years to understand that these repeat infections might signal something deeper like primary immunodeficiency \(PI\). Up to 90% of people with PI don’t know they have it. Many spend years searching for answers, seeing multiple specialists, and still feeling stuck in the same cycle. That’s why CSL created SickonRepeat.com, a new educational resource designed to help people recognize patterns in their health, understand the signs of PI, and feel more confident starting important conversations with their healthcare provider. The site offers: • Clear, simple information about PI • What the common signs of PI are • Support and options for next steps to take If you or someone you know feels “sick on repeat,” know this: you’re not imagining it and you’re not alone. ➡️ Visit SickonRepeat.com to learn more and take the first step toward answers. #PrimaryImmunodeficiency #PI #RareDisease
CSL's 2026 Half Year Financial Results
We have announced our 2026 Half Year Financial Results for the period ending 31st December 2025.
Like to learn more about Our Impact? Click here to view or download the 2025 Impact Report → | Would you like to read our 2025 Annual Report? Click here to view or download the Annual Report → | CSL's 2025 Full Year Financial Results Click here for Full Information including Webcast Recording →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
As we approach Rare Disease Day, we’re raising awareness of ANCA-associated vasculitis \(AAV\) — a rare autoimmune disease that causes inflammation in small blood vessels and can lead to serious organ damage. Because symptoms can vary widely and affect multiple organs, diagnosis can be complex and delayed. Greater awareness can help improve understanding and support earlier recognition. Rare diseases may affect small patient populations, but their impact is profound — for individuals, families, and healthcare systems. Learn more about AAV at: www.myancavasculitis.com #RareDiseaseDay #ANCAvasculitis #RareDiseases #AutoimmuneDisease #CSL
CSL is the world’s only maker of antivenoms for native Australian species — a critical role in protecting public health and saving lives. Behind this achievement is a team of passionate people committed to science and impact. Join CSL and help us tackle global health challenges: https://bit.ly/40kadfc #CSL #CSLImpactReport #CSLCareers #PromisingFutures
Flu season hits hardest when temperatures and humidity drop, which is why winter brings waves of illness across the globe. At CSL, we’re working to stay ahead of the virus with science that protects, adapts, and helps save lives. Click the link to learn more about our impact in fighting the flu: https://lnkd.in/eQiPYqdg #CSL #CSLImpactReport #SeasonalInfluenza #Seqirus
As we approach Rare Disease Day on February 28, learn more about hereditary angioedema \(HAE\), a rare condition that causes dangerous swelling attacks. https://lnkd.in/egYtJAWB #CSL #RareDiseaseDay #HereditaryAngioedema #HAEAwareness #KnowHAE
When choosing a treatment plan for hereditary angioedema \(HAE\), health care providers are experts in medical matters, but patients are the experts in what matters most to them. They understand firsthand what daily life with HAE looks like. A collaborative approach called shared decision-making recognizes there are two experts in the room – full partners who can make informed, meaningful decisions together. With so many treatment options available today – each with different dosing schedules, administration methods and benefits – health care providers and people living with HAE can explore these choices together in a way that reflects personal goals, concerns and day-to day-realities. In this blog post featured on the U.S. Hereditary Angioedema Association \(HAEA\) website, a medical specialist shares insights on how health care teams and patients are bringing this approach to life: https://bit.ly/3OpTB32. #HAE #SharedDecisionMaking #RareDisease #CSL
Today, we announced an exclusive licencing agreement with Eli Lilly and Company granting certain rights to develop and commercialise clazakizumab, an anti-interleukin-6 \(IL-6\) monoclonal antibody. CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with ESKD. Read more: https://bit.ly/4rp9Ls8
As the need for advanced fibrinogen therapies grows, CSL teams are driving innovation that strengthens surgical care, trauma treatment and emergency medicine worldwide. Our work in fibrinogen science reflects the expertise and impact behind every product we deliver. Shape what’s possible in life sciences: https://bit.ly/3MOJd4m #CSLCareers #Innovation #BiotechCareers #LifeSciences #CSL
Rare Disease Day is February 28th. To shine a light on those battling rare diseases, today we’re highlighting von Willebrand Disease or \(VWD\). According to the CDC, von Willebrand Disease is the most common blood disorder. https://lnkd.in/gZZmTNHx #CSL #RareDiseaseDay #RDD #VWD #VonWillebrandDisease
CSL is the world’s only maker of antivenoms for many native venomous Australian species. Click the link to learn more about how we are serving a significant public health need: csl.com/impact #CSL #CSLImpactReport #Antivenom #Seqirus